This company recently went public with an IPO on Wednesday, August 5th 2026. They issued 12,500,000 shares at $15.00 - $17.00 per share. We will continue to update data for ATTO as it becomes available. NASDAQ:ATTO Attovia Therapeutics (ATTO) Stock Price, News & Analysis $20.38 -1.52 (-6.94%) As of 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesTrendsBuy This Stock About Attovia Therapeutics Stock (NASDAQ:ATTO) Get Attovia Therapeutics alerts:Sign Up Key Stats Today's Range$19.63▼$22.0550-Day Range N/A52-Week Range$19.63▼$22.79Volume413,197 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs. Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. Its pipeline is centered on potential treatments for conditions involving dysregulated immune responses, although many of its programs remain in development and are subject to clinical and regulatory evaluation. As a development-stage biotechnology company, Attovia’s activities primarily involve research, preclinical studies, clinical trials and the advancement of its proprietary therapeutic pipeline. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on developing innovative treatments for inflammatory diseases.AI Generated. May Contain Errors. Read More Receive ATTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Attovia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATTO Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com ATTO Stock Analysis - Frequently Asked Questions When did Attovia Therapeutics IPO? Attovia Therapeutics (ATTO) raised $200 million in an initial public offering (IPO) on Wednesday, August 5th 2026. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. When does Attovia Therapeutics' quiet period expire? Attovia Therapeutics's quiet period expires on Monday, September 14th. Attovia Therapeutics had issued 17,000,000 shares in its IPO on August 5th. The total size of the offering was $289,000,000 based on an initial share price of $17.00. During Attovia Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Attovia Therapeutics? Shares of ATTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ATTO CIKN/A WebN/A Phone(510) 399-5001FaxN/AEmployees44Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ATTO) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersA Wall Street Veteran's Weekly Trade for Any Market ConditionDave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...Base Camp Trading | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Attovia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Attovia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.